<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110603</url>
  </required_header>
  <id_info>
    <org_study_id>2010_528</org_study_id>
    <secondary_id>MK-4827-008</secondary_id>
    <nct_id>NCT01110603</nct_id>
  </id_info>
  <brief_title>A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)</brief_title>
  <official_title>A Phase Ib Dose Escalation Study of MK-4827 in Combination With Carboplatin, Carboplatin/Paclitaxel and Carboplatin/Liposomal Doxorubicin in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tesaro, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will find the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and
      recommended Phase 2 dose (RPTD) of MK4827 when administered in combination with standard
      doses of carboplatin, or carboplatin/paclitaxel, or carboplatin/liposomal doxorubicin in the
      treatment of advanced solid cancers in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The decision to discontinue new enrollment is not related to any concerns about the safety
      profile of the product.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Each cycle (21 or 28 Days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinical and laboratory adverse events (AEs)</measure>
    <time_frame>Baseline to 30 days post last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cancer: Solid Tumors</condition>
  <arm_group>
    <arm_group_label>MK-4827 + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4827 + carboplatin/paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-4827 + carboplatin/liposomal doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-4827</intervention_name>
    <description>Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.</description>
    <arm_group_label>MK-4827 + carboplatin</arm_group_label>
    <arm_group_label>MK-4827 + carboplatin/paclitaxel</arm_group_label>
    <arm_group_label>MK-4827 + carboplatin/liposomal doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle</description>
    <arm_group_label>MK-4827 + carboplatin</arm_group_label>
    <arm_group_label>MK-4827 + carboplatin/paclitaxel</arm_group_label>
    <arm_group_label>MK-4827 + carboplatin/liposomal doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle</description>
    <arm_group_label>MK-4827 + carboplatin/paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal doxorubicin</intervention_name>
    <description>Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle</description>
    <arm_group_label>MK-4827 + carboplatin/liposomal doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has a locally advanced or metastatic solid tumor for which carboplatin,
             carboplatin/paclitaxel, or carboplatin/liposomal doxorubicin are the standard of care.

          -  Participant has a performance status of 0 or 1 on the Eastern Cooperative Oncology
             Group (ECOG) Performance Scale.

        Exclusion Criteria:

          -  Participant has had chemotherapy, radiotherapy, or biological therapy within 4 weeks
             prior to entering the study.

          -  Participant has had more than two prior lines of chemotherapy.

          -  Participant has known central nervous system metastases or a primary central nervous
             system tumor.

          -  Participant is pregnant or breastfeeding or expecting to conceive during the timeframe
             of the study.

          -  Participant is known to be human immunodeficiency virus (HIV) positive.

          -  Participant has a history of Hepatitis B or C.

          -  Participant has a symptomatic pleural effusion.

          -  Participant with a left ventricular ejection fraction (LVEF) below the institutional
             norm, or with prior exposure to doxorubicin is not eligible for the MK4827 +
             carboplatin/liposomal doxorubicin study arm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2010</study_first_posted>
  <last_update_submitted>May 4, 2016</last_update_submitted>
  <last_update_submitted_qc>May 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Niraparib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

